Federated Investors Inc. PA decreased its position in Spark Therapeutics (NASDAQ:ONCE) by 19.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,497,788 shares of the biotechnology company’s stock after selling 353,612 shares during the period. Federated Investors Inc. PA owned approximately 4.02% of Spark Therapeutics worth $99,738,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also recently modified their holdings of ONCE. Silvant Capital Management LLC purchased a new position in shares of Spark Therapeutics during the 1st quarter valued at about $141,000. Public Employees Retirement Association of Colorado purchased a new position in shares of Spark Therapeutics during the 4th quarter valued at about $163,000. Aperio Group LLC raised its stake in shares of Spark Therapeutics by 29.2% during the 4th quarter. Aperio Group LLC now owns 3,972 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 898 shares during the last quarter. Xact Kapitalforvaltning AB purchased a new position in shares of Spark Therapeutics during the 4th quarter valued at about $208,000. Finally, Paloma Partners Management Co purchased a new position in shares of Spark Therapeutics during the 4th quarter valued at about $239,000.
NASDAQ:ONCE opened at $73.09 on Tuesday. Spark Therapeutics has a 52 week low of $41.06 and a 52 week high of $91.75. The stock has a market cap of $2.87 billion, a PE ratio of -9.58 and a beta of 2.54.
Spark Therapeutics (NASDAQ:ONCE) last posted its earnings results on Tuesday, May 8th. The biotechnology company reported ($1.25) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.45) by ($0.80). Spark Therapeutics had a negative net margin of 935.38% and a negative return on equity of 51.76%. The business had revenue of $15.68 million for the quarter, compared to analyst estimates of $51.55 million. During the same quarter last year, the business earned ($1.70) earnings per share. Spark Therapeutics’s revenue was up 1134.6% on a year-over-year basis. analysts predict that Spark Therapeutics will post -3.47 earnings per share for the current fiscal year.
In related news, COO John Furey sold 20,000 shares of Spark Therapeutics stock in a transaction dated Thursday, April 12th. The stock was sold at an average price of $77.51, for a total value of $1,550,200.00. Following the sale, the chief operating officer now directly owns 20,000 shares in the company, valued at approximately $1,550,200. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last quarter, insiders sold 40,000 shares of company stock worth $3,200,466. 5.90% of the stock is currently owned by insiders.
A number of equities analysts have weighed in on the company. Cantor Fitzgerald reiterated a “buy” rating and set a $103.00 price objective (up previously from $100.00) on shares of Spark Therapeutics in a research note on Monday, April 30th. Chardan Capital lowered Spark Therapeutics from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $80.00 to $85.00 in a research note on Monday, April 23rd. BMO Capital Markets set a $64.00 price objective on Spark Therapeutics and gave the company a “buy” rating in a research note on Wednesday, February 21st. ValuEngine upgraded Spark Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 9th. Finally, Mizuho reiterated a “buy” rating and set a $91.00 price objective on shares of Spark Therapeutics in a research note on Tuesday, May 1st. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $76.10.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.